Prior treatments were similar in case of antiplatelets and statins, anticoagulants were more used by the COVID-19-positive patients (27.8% vs 9.2%; P = .009), while ACE inhibitors were less used (11.1% vs 44.4%; P = .001). Here, ACE is linked to COVID-19.